Amicus Therapeutics, Inc. (FRA:AM6)
12.00
0.00 (0.00%)
Last updated: Jan 6, 2026, 8:03 AM CET
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $169.06M USD in the quarter ending September 30, 2025, with 19.46% growth. This brings the company's revenue in the last twelve months to $598.70M, up 21.28% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$598.70M
Revenue Growth
+21.28%
P/S Ratio
7.44
Revenue / Employee
$1.20M
Employees
499
Market Cap
3.80B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
| Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
| Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
| Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
| Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
| Dec 31, 2019 | 182.24M | 90.99M | 99.72% |
| Dec 31, 2018 | 91.25M | 54.32M | 147.08% |
| Dec 31, 2017 | 36.93M | 31.97M | 644.86% |
| Dec 31, 2016 | 4.96M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 1.22M | 861.00K | 237.19% |
| Dec 31, 2013 | 363.00K | -18.05M | -98.03% |
| Dec 31, 2012 | 18.41M | -3.02M | -14.10% |
| Dec 31, 2011 | 21.43M | 20.51M | 2,224.73% |
| Dec 31, 2010 | 922.00K | -63.44M | -98.57% |
| Dec 31, 2009 | 64.36M | 49.39M | 330.00% |
| Dec 31, 2008 | 14.97M | 13.18M | 738.96% |
| Dec 31, 2007 | 1.78M | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
Amicus Therapeutics News
- 13 days ago - Noteworthy ETF Inflows: XBI, FOLD, MRNA, EXEL - Nasdaq
- 16 days ago - Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD - Business Wire
- 18 days ago - BioMarin Pharmaceutical Inc. (BMRN) Amicus Therapeutics, Inc., - M&A Call - Slideshow - Seeking Alpha
- 18 days ago - Is the Market Bullish or Bearish on Amicus Therapeutics Inc? - Benzinga
- 19 days ago - What's Going On With BioMarin Stock On Tuesday? - Benzinga
- 20 days ago - BioMarin: Amicus Buyout Sparks My Enthusiasm - Seeking Alpha
- 20 days ago - Amicus Therapeutics (FOLD) Sees Analyst Rating Downgrade from Citigroup | FOLD Stock News - GuruFocus
- 23 days ago - BioMarin Stock Surges Nearly 20% After $4.8 Bln Amicus Acquisition News - Nasdaq